Abstract
Data are presented of 368/503 post-COVID-19 outpatients followed within the AntiCROWN Cohort who have a one-year control and a baseline assessment of anti-S1/S2 antibodies, detected with the The LIAISON® SARS-CoV-2 S1/S2 IgG solution by DiaSorin. Loss of response occurred in 4 subjects having a baseline level below 50 AU/mL.
Keywords: Antibodies; COVID-19; Coronavirus; Durability; Observational; Spike.
All Keywords
【저자키워드】 COVID-19, antibodies, coronavirus, spike, Observational, Durability, 【초록키워드】 SARS-CoV-2, IgG, spike, Anti-S1, Outpatient, subject, DiaSorin, Baseline assessment, S1/S2, Loss, occurred, baseline, 【제목키워드】 prospective observational study, anti-Spike IgG,
【저자키워드】 COVID-19, antibodies, coronavirus, spike, Observational, Durability, 【초록키워드】 SARS-CoV-2, IgG, spike, Anti-S1, Outpatient, subject, DiaSorin, Baseline assessment, S1/S2, Loss, occurred, baseline, 【제목키워드】 prospective observational study, anti-Spike IgG,
{{{ 추상적인 }}}
LIAISON® SARS-CoV-2 S1/로 검출된 항-S1/S2 항체에 대한 1년 통제 및 기준 평가를 받은 AntiCROWN 코호트 내에서 추적한 368/503명의 COVID-19 이후 외래 환자의 데이터가 제공됩니다. DiaSorin의 S2 IgG 용액. 기준선 수준이 50AU/mL 미만인 4명의 대상체에서 반응 상실이 발생했습니다.
{{ 키워드: }} 항체; 코로나바이러스감염증-19 : 코로나19; 코로나바이러스; 내구성; 관찰적; 스파이크.